News articles about West Pharmaceutical Services (NYSE:WST) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. West Pharmaceutical Services earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 46.2838019073552 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of West Pharmaceutical Services (WST) traded down $0.01 during trading on Friday, reaching $99.63. 331,592 shares of the company’s stock were exchanged, compared to its average volume of 345,404. The stock has a market cap of $7,400.00, a P/E ratio of 42.94, a P/E/G ratio of 2.12 and a beta of 1.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.87 and a current ratio of 2.59. West Pharmaceutical Services has a 52 week low of $77.97 and a 52 week high of $103.36.
West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.14. The company had revenue of $398.20 million during the quarter, compared to the consensus estimate of $386.02 million. West Pharmaceutical Services had a net margin of 12.12% and a return on equity of 14.47%. West Pharmaceutical Services’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.53 EPS. equities analysts anticipate that West Pharmaceutical Services will post 2.76 EPS for the current year.
WST has been the subject of several research reports. Jefferies Group upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and upped their price target for the company from $96.00 to $115.00 in a research report on Friday, September 15th. Stephens initiated coverage on shares of West Pharmaceutical Services in a research report on Tuesday, October 3rd. They issued an “equal weight” rating and a $99.00 price target for the company. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Wednesday, September 27th. Bank of America downgraded shares of West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price objective for the company. in a research report on Tuesday, October 17th. Finally, Wells Fargo & Company upped their price objective on shares of West Pharmaceutical Services from $105.00 to $112.00 and gave the stock an “outperform” rating in a research report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. West Pharmaceutical Services currently has an average rating of “Hold” and an average target price of $106.00.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.